Reference #: 1729
The University of South Carolina is offering licensing opportunities for Aminergic phytocannabinoids derivatives as multi-target agents for neurological disorders.
Background:
The medicinal properties of certain aminergic cannabinoid derivatives are currently being explored, but preliminary data shows they may possess potential to act in the brain as anti-depressants, anxiolytics, and/or non-traditional anti-psychotics. Moreover, recent data suggests that these aminergic cannabinoids may exhibit the ability to treat or delay the onset of neurodegenerative conditions. These effects are mediated centrally through simultaneous regulation of sigma-1, serotonin, and dopamine receptors, and may also act peripherally to prevent pain or the onset of valvular heart conditions through sigma-2 receptors and serotonin receptors, respectively.
Invention Description:
The innovation herein describes the production method and eventual clinical application of a novel class of drug created from natural cannabis extracts. The novel synthetic strategy developed herein can be used to access never-before-seen cannabinoids from the primary components of cannabis, cannabidiol (CBD) and delta-9-THC (Δ9-THC). Cannabidiol (CBD) isolated from crude hemp extract is transformed through a sequence of reactions to produce a product which may be subsequently used as the starting material to introduce new nitrogen- or oxygen-containing functionalities.
Potential Applications:
This production method and application of aminergic cannabinoids may lead to novel clinical therapeutics or biochemical probes for a variety of health conditions, including, but not limited to, neurodegenerative disorders (Alzheimer’s disease, Parkinson’s Disease, Huntington’s Disease, ALS, etc.), mood disorders, and valvular heart conditions.
Advantages and Benefits:
The compounds afforded by this production method allow for regulation of different neuronal signaling pathways simultaneously, as opposed to the classical drug design strategy which selectively modifies singular targets. This approach should theoretically allow for greater control over neurotransmitter balance or neuronal activity across entire circuits or regions of the brain to provide a more comprehensive method of treating central nervous system disorders.